Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound generated $14.8 billion in Q2 revenue ($9.9 billion from Mounjaro and $4.9 billion from Zepbound), driving nearly 48% year-over-year company sales growth.
Sep 12, 2026 ·
Yahoo Finance











